<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055937</url>
  </required_header>
  <id_info>
    <org_study_id>VA2012/37</org_study_id>
    <secondary_id>2012-A01369-34</secondary_id>
    <nct_id>NCT02055937</nct_id>
  </id_info>
  <brief_title>Immediate Implant Breast Reconstruction</brief_title>
  <acronym>ISIS</acronym>
  <official_title>Immediate Implant Breast Reconstruction for Patients With Mastectomy Ans Post opérative Chest Wall Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the impact of the immediate implant breast&#xD;
      reconstruction for patients with mastectomy and postoperative chest wall radiotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      non applicable&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    autorities vorbidden this dispositif in other trial&#xD;
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success is defined as a complete therapeutic sequence (surgery + RT) without any significant complication at 6 months.</measure>
    <time_frame>confirm the feasibility of the therapeutic sequence at 6 months</time_frame>
    <description>Success is defined as a complete therapeutic sequence (surgery + RT) without any significant complication at 6 months.&#xD;
Significant complication is defined as:&#xD;
Any event delaying RT (delay surgery/RT &gt; 3 months)&#xD;
Any event preventing patients from receiving radiotherapy within 6 months after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of Baker</measure>
    <time_frame>up to 36 months after surgery</time_frame>
    <description>The rate of Baker grades 3/4 capsular contracture</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cosmetic results</measure>
    <time_frame>up to 36 months after surgery</time_frame>
    <description>Cosmetic results: assessed by both the surgeon and patient (patient satisfaction will be evaluated using a self-questionnaire). Photographs of the breast will be taken at different times (Pre / per / postoperative) and the picture analysis will be reviewed by an independent committee.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional results</measure>
    <time_frame>up to 36 months after surgery</time_frame>
    <description>Functional results: patient satisfaction will be evaluated using a self-questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>The rate of patients requiring breast implant removal</measure>
    <time_frame>up to 36 months after surgery</time_frame>
    <description>The rate of patients requiring breast implant removal</description>
  </other_outcome>
  <other_outcome>
    <measure>Study of tolerance</measure>
    <time_frame>up to 36 months after surgery</time_frame>
    <description>Study of the indesirable effect of the radiotherapy on the implant</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>immediate implant breast reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immediate implant breast reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immediate implant breast reconstruction</intervention_name>
    <description>Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™</description>
    <arm_group_label>immediate implant breast reconstruction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed breast carcinoma&#xD;
&#xD;
          -  Patients planned for mastectomy with immediate single stage breast reconstruction&#xD;
             using an acellular dermal matrix (Strattice™, LifeCell Corporation)&#xD;
&#xD;
          -  Patients planned to receive postoperative chest wall irradiation&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
          -  Informed consent signed prior any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Tumors with extensive involvement of the skin&#xD;
&#xD;
          -  Use of tissue expander&#xD;
&#xD;
          -  Indication of postoperative chemotherapy&#xD;
&#xD;
          -  Patients planned for bilateral mastectomy&#xD;
&#xD;
          -  History of previously treated ipsilateral breast carcinoma&#xD;
&#xD;
          -  Usual contraindications for ADM&#xD;
&#xD;
          -  Medical debility precluding surgical treatment&#xD;
&#xD;
          -  Psychological, social, geographical disorders or any other condition that would&#xD;
             preclude study compliance (treatment modalities and study follow-up).&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Inability to attend or comply with interventions or follow-up scheduling, disability&#xD;
             or difficulty preventing a proper understanding of trial instructions&#xD;
&#xD;
          -  Legal inability or restricted legal ability&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut régional du Cancer - Montpellier - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Christian CK, Niland J, Edge SB, Ottesen RA, Hughes ME, Theriault R, Wilson J, Hergrueter CA, Weeks JC. A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg. 2006 Feb;243(2):241-9.</citation>
    <PMID>16432358</PMID>
  </reference>
  <reference>
    <citation>Lambert K, Mokbel K. Does post-mastectomy radiotherapy represent a contraindication to skin-sparing mastectomy and immediate reconstruction: an update. Surg Oncol. 2012 Jun;21(2):e67-74. doi: 10.1016/j.suronc.2011.12.007. Epub 2012 Jan 30. Review.</citation>
    <PMID>22296996</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mastectomy, reconstruction</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

